 Adriaan Van Bokhoven
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 30 | 2015 | 921 | 1.580 |
Why?
| | Carcinoma | 4 | 2011 | 198 | 0.560 |
Why?
| | Prostate | 12 | 2015 | 156 | 0.480 |
Why?
| | Cadherins | 12 | 2007 | 175 | 0.440 |
Why?
| | Cell Line, Tumor | 7 | 2015 | 2710 | 0.380 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2011 | 196 | 0.300 |
Why?
| | Tumor Cells, Cultured | 11 | 2008 | 849 | 0.290 |
Why?
| | Pelvic Pain | 3 | 2015 | 32 | 0.270 |
Why?
| | Finasteride | 2 | 2015 | 35 | 0.220 |
Why?
| | Carcinoma, Renal Cell | 4 | 2008 | 168 | 0.190 |
Why?
| | Biopsy | 2 | 2015 | 1036 | 0.180 |
Why?
| | Cell Lineage | 1 | 2001 | 309 | 0.160 |
Why?
| | Cystitis, Interstitial | 2 | 2015 | 16 | 0.160 |
Why?
| | Receptors, Androgen | 2 | 2014 | 131 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2012 | 445 | 0.150 |
Why?
| | Prostatitis | 2 | 2015 | 18 | 0.150 |
Why?
| | Immunohistochemistry | 8 | 2015 | 1629 | 0.140 |
Why?
| | Male | 38 | 2015 | 55583 | 0.140 |
Why?
| | Androstenedione | 1 | 2015 | 10 | 0.120 |
Why?
| | Urinary Tract | 1 | 2015 | 36 | 0.120 |
Why?
| | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2008 | 9 | 0.120 |
Why?
| | DNA, Neoplasm | 5 | 2003 | 157 | 0.120 |
Why?
| | Kidney Neoplasms | 4 | 2008 | 327 | 0.120 |
Why?
| | Prostatic Hyperplasia | 1 | 2015 | 38 | 0.120 |
Why?
| | Proteinuria | 1 | 2014 | 77 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 7 | 2011 | 923 | 0.120 |
Why?
| | Trinucleotide Repeats | 1 | 2014 | 24 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2015 | 1141 | 0.110 |
Why?
| | Adaptive Immunity | 1 | 2015 | 155 | 0.110 |
Why?
| | Karyotyping | 3 | 2003 | 102 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2014 | 51 | 0.110 |
Why?
| | Chromosome Aberrations | 3 | 2003 | 135 | 0.110 |
Why?
| | B7-H1 Antigen | 1 | 2015 | 139 | 0.110 |
Why?
| | Serine Endopeptidases | 1 | 2014 | 102 | 0.110 |
Why?
| | Optics and Photonics | 1 | 2014 | 41 | 0.110 |
Why?
| | Biopsy, Needle | 1 | 2014 | 182 | 0.110 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 157 | 0.110 |
Why?
| | Blotting, Western | 5 | 2012 | 1147 | 0.100 |
Why?
| | Androstane-3,17-diol | 1 | 2012 | 2 | 0.100 |
Why?
| | 5-alpha Reductase Inhibitors | 1 | 2012 | 16 | 0.100 |
Why?
| | Inflammation | 2 | 2015 | 2478 | 0.100 |
Why?
| | Glucuronides | 1 | 2012 | 12 | 0.100 |
Why?
| | Humans | 48 | 2015 | 114662 | 0.100 |
Why?
| | Cell Adhesion | 4 | 2004 | 431 | 0.100 |
Why?
| | Proto-Oncogenes | 1 | 1992 | 26 | 0.100 |
Why?
| | Chronic Pain | 1 | 2015 | 210 | 0.100 |
Why?
| | Polymorphism, Genetic | 2 | 2008 | 610 | 0.100 |
Why?
| | Cadmium | 1 | 2012 | 58 | 0.100 |
Why?
| | Urothelium | 1 | 2011 | 33 | 0.090 |
Why?
| | Gonadal Steroid Hormones | 1 | 2012 | 124 | 0.090 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2011 | 59 | 0.090 |
Why?
| | Cell Division | 3 | 2011 | 758 | 0.090 |
Why?
| | Epithelial Cells | 4 | 2012 | 950 | 0.090 |
Why?
| | Immunity, Innate | 1 | 2015 | 720 | 0.080 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2011 | 309 | 0.080 |
Why?
| | Biomarkers | 3 | 2015 | 3408 | 0.080 |
Why?
| | Proteins | 1 | 2014 | 908 | 0.080 |
Why?
| | Bacteria | 1 | 2015 | 725 | 0.080 |
Why?
| | Dogs | 3 | 2011 | 334 | 0.080 |
Why?
| | Clinical Medicine | 1 | 2008 | 19 | 0.080 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1992 | 395 | 0.080 |
Why?
| | Biomedical Research | 1 | 2014 | 585 | 0.080 |
Why?
| | Cell Adhesion Molecules | 2 | 2007 | 168 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 1 | 1992 | 608 | 0.080 |
Why?
| | Microbiota | 1 | 2015 | 647 | 0.080 |
Why?
| | Receptors, Calcitriol | 1 | 2008 | 53 | 0.070 |
Why?
| | Catenins | 1 | 2007 | 5 | 0.070 |
Why?
| | Promoter Regions, Genetic | 4 | 2000 | 1131 | 0.070 |
Why?
| | RNA, Messenger | 5 | 2006 | 2552 | 0.070 |
Why?
| | Brain Neoplasms | 2 | 2012 | 979 | 0.070 |
Why?
| | Antibodies, Monoclonal | 2 | 1993 | 1262 | 0.070 |
Why?
| | Osteolysis | 1 | 2006 | 14 | 0.070 |
Why?
| | Biomarkers, Tumor | 3 | 2008 | 1040 | 0.070 |
Why?
| | Bone Development | 1 | 2006 | 47 | 0.070 |
Why?
| | Soybean Proteins | 1 | 2006 | 10 | 0.070 |
Why?
| | Isoflavones | 1 | 2006 | 16 | 0.070 |
Why?
| | Molecular Sequence Data | 11 | 2000 | 2785 | 0.070 |
Why?
| | Base Sequence | 10 | 2000 | 2114 | 0.060 |
Why?
| | Middle Aged | 11 | 2015 | 26733 | 0.060 |
Why?
| | Transplantation, Heterologous | 3 | 2012 | 181 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2007 | 298 | 0.060 |
Why?
| | Cloning, Molecular | 6 | 2000 | 522 | 0.060 |
Why?
| | Cytoskeletal Proteins | 3 | 2000 | 145 | 0.060 |
Why?
| | Urinalysis | 2 | 2015 | 64 | 0.060 |
Why?
| | Chromosomes, Human, Pair 16 | 2 | 1995 | 30 | 0.060 |
Why?
| | Aged, 80 and over | 6 | 2015 | 6345 | 0.060 |
Why?
| | Gene Deletion | 2 | 1996 | 356 | 0.060 |
Why?
| | Spectral Karyotyping | 1 | 2003 | 5 | 0.060 |
Why?
| | DNA Fingerprinting | 1 | 2003 | 26 | 0.060 |
Why?
| | Aged | 9 | 2015 | 19069 | 0.060 |
Why?
| | Bone Neoplasms | 3 | 2012 | 194 | 0.060 |
Why?
| | Chromosomes, Human, Pair 9 | 2 | 2000 | 43 | 0.050 |
Why?
| | Keratins | 1 | 2003 | 176 | 0.050 |
Why?
| | Apoptosis | 1 | 2012 | 2362 | 0.050 |
Why?
| | DNA Primers | 2 | 2001 | 510 | 0.050 |
Why?
| | Prostate-Specific Antigen | 1 | 2003 | 151 | 0.050 |
Why?
| | Nerve Tissue Proteins | 3 | 1993 | 529 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2015 | 1083 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2015 | 3003 | 0.050 |
Why?
| | Blotting, Northern | 6 | 2000 | 193 | 0.050 |
Why?
| | DNA Mutational Analysis | 2 | 2001 | 372 | 0.050 |
Why?
| | Carrier Proteins | 2 | 1996 | 695 | 0.050 |
Why?
| | Precancerous Conditions | 1 | 2003 | 158 | 0.050 |
Why?
| | Chromosome Mapping | 4 | 1999 | 487 | 0.050 |
Why?
| | Prostatectomy | 2 | 2013 | 98 | 0.050 |
Why?
| | Cytogenetics | 1 | 2001 | 11 | 0.050 |
Why?
| | Genes, Neoplasm | 1 | 2001 | 20 | 0.050 |
Why?
| | Polymerase Chain Reaction | 5 | 2008 | 993 | 0.050 |
Why?
| | Genes, ras | 1 | 2001 | 91 | 0.050 |
Why?
| | Mice, Nude | 3 | 2011 | 630 | 0.050 |
Why?
| | Adenocarcinoma | 2 | 2012 | 795 | 0.040 |
Why?
| | Neoplasm Proteins | 2 | 2000 | 384 | 0.040 |
Why?
| | Activated-Leukocyte Cell Adhesion Molecule | 1 | 2000 | 1 | 0.040 |
Why?
| | Carbonic Anhydrases | 1 | 2000 | 13 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2085 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2003 | 463 | 0.040 |
Why?
| | Phenotype | 3 | 2015 | 2796 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2000 | 162 | 0.040 |
Why?
| | HeLa Cells | 1 | 2001 | 562 | 0.040 |
Why?
| | Pituitary Hormones | 2 | 1989 | 16 | 0.040 |
Why?
| | Risk | 2 | 2012 | 812 | 0.040 |
Why?
| | Parathyroid Hormone-Related Protein | 2 | 2011 | 21 | 0.040 |
Why?
| | Cell Communication | 1 | 2000 | 279 | 0.040 |
Why?
| | Transcription, Genetic | 3 | 2000 | 1313 | 0.040 |
Why?
| | Cell Separation | 2 | 2011 | 291 | 0.040 |
Why?
| | RNA | 3 | 2000 | 809 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2000 | 222 | 0.040 |
Why?
| | Neoplasm Transplantation | 2 | 2011 | 228 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2015 | 2387 | 0.040 |
Why?
| | Prognosis | 3 | 2015 | 3329 | 0.040 |
Why?
| | Telomerase | 1 | 2000 | 206 | 0.040 |
Why?
| | Trans-Activators | 1 | 2000 | 367 | 0.040 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2000 | 216 | 0.040 |
Why?
| | Animals | 12 | 2012 | 31699 | 0.040 |
Why?
| | Incidence | 2 | 2015 | 2313 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2014 | 2763 | 0.030 |
Why?
| | Restriction Mapping | 4 | 1999 | 77 | 0.030 |
Why?
| | Schistosomiasis | 1 | 1996 | 37 | 0.030 |
Why?
| | Female | 8 | 2015 | 59493 | 0.030 |
Why?
| | alpha Catenin | 3 | 2000 | 13 | 0.030 |
Why?
| | Transfection | 3 | 2006 | 866 | 0.030 |
Why?
| | Disease Progression | 3 | 2015 | 2380 | 0.030 |
Why?
| | Mice | 7 | 2012 | 14863 | 0.030 |
Why?
| | Point Mutation | 1 | 1996 | 216 | 0.030 |
Why?
| | Tosyl Compounds | 1 | 2015 | 14 | 0.030 |
Why?
| | Urine | 1 | 2015 | 54 | 0.030 |
Why?
| | Maryland | 1 | 2015 | 37 | 0.030 |
Why?
| | DNA | 4 | 2000 | 1352 | 0.030 |
Why?
| | Anilides | 1 | 2015 | 67 | 0.030 |
Why?
| | CD8 Antigens | 1 | 2015 | 69 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 2015 | 75 | 0.030 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 53 | 0.030 |
Why?
| | Chemical Precipitation | 1 | 2014 | 37 | 0.030 |
Why?
| | Neoplasm Metastasis | 2 | 2011 | 523 | 0.030 |
Why?
| | Nitriles | 1 | 2015 | 149 | 0.030 |
Why?
| | CD4 Antigens | 1 | 2015 | 123 | 0.030 |
Why?
| | National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 9 | 0.030 |
Why?
| | Genes | 1 | 1995 | 223 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2015 | 140 | 0.030 |
Why?
| | Reference Standards | 1 | 2014 | 159 | 0.030 |
Why?
| | Cell Line | 4 | 1994 | 2636 | 0.030 |
Why?
| | Amino Acid Sequence | 5 | 2000 | 1982 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 242 | 0.030 |
Why?
| | Support Vector Machine | 1 | 2014 | 34 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 70 | 0.030 |
Why?
| | Specimen Handling | 1 | 2014 | 155 | 0.030 |
Why?
| | Syndrome | 1 | 2014 | 333 | 0.030 |
Why?
| | Needles | 1 | 2014 | 49 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 84 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2015 | 4411 | 0.030 |
Why?
| | Binding Sites | 2 | 1997 | 1168 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 183 | 0.030 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 1879 | 0.030 |
Why?
| | Antigens, CD | 1 | 2015 | 442 | 0.030 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2012 | 48 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 807 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-fes | 1 | 1992 | 1 | 0.030 |
Why?
| | Exons | 3 | 1999 | 302 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2015 | 719 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 508 | 0.020 |
Why?
| | Calcium | 2 | 1994 | 1108 | 0.020 |
Why?
| | Vimentin | 1 | 1992 | 58 | 0.020 |
Why?
| | Retroviridae | 1 | 1992 | 90 | 0.020 |
Why?
| | Adult | 5 | 2015 | 30544 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 3 | 2000 | 353 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 318 | 0.020 |
Why?
| | Carcinogenicity Tests | 1 | 2011 | 5 | 0.020 |
Why?
| | Keratin-8 | 1 | 2011 | 3 | 0.020 |
Why?
| | Adenoviridae | 1 | 2012 | 184 | 0.020 |
Why?
| | Neoplasms, Connective Tissue | 1 | 2011 | 3 | 0.020 |
Why?
| | Keratin-7 | 1 | 2011 | 2 | 0.020 |
Why?
| | Keratin-18 | 1 | 2011 | 10 | 0.020 |
Why?
| | Subcutaneous Tissue | 1 | 2011 | 17 | 0.020 |
Why?
| | Phenylbutyrates | 1 | 2011 | 21 | 0.020 |
Why?
| | Bortezomib | 1 | 2011 | 41 | 0.020 |
Why?
| | Spinal Cord Neoplasms | 1 | 2011 | 37 | 0.020 |
Why?
| | Boronic Acids | 1 | 2011 | 33 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2011 | 134 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 1660 | 0.020 |
Why?
| | Pyrazines | 1 | 2011 | 71 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 38 | 0.020 |
Why?
| | Atrophy | 1 | 2010 | 152 | 0.020 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2011 | 81 | 0.020 |
Why?
| | DNA, Viral | 1 | 1992 | 350 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 535 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 396 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 1992 | 430 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 797 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1692 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 872 | 0.020 |
Why?
| | Cell Cycle | 1 | 2012 | 542 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 1992 | 616 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2012 | 3885 | 0.020 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 1989 | 53 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2010 | 181 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 1995 | 2319 | 0.020 |
Why?
| | Research Design | 1 | 2014 | 928 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1578 | 0.020 |
Why?
| | Silymarin | 1 | 2010 | 194 | 0.020 |
Why?
| | Risk Factors | 2 | 2014 | 8632 | 0.020 |
Why?
| | Primaquine | 1 | 1988 | 2 | 0.020 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2010 | 286 | 0.020 |
Why?
| | Signal Transduction | 2 | 2015 | 4512 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 1988 | 43 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2000 | 723 | 0.020 |
Why?
| | Terminology as Topic | 1 | 2008 | 187 | 0.020 |
Why?
| | Sequence Alignment | 2 | 2000 | 323 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2010 | 1121 | 0.020 |
Why?
| | Introns | 2 | 1999 | 227 | 0.020 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 1996 | 25 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1988 | 201 | 0.020 |
Why?
| | Antioxidants | 1 | 2010 | 530 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 1996 | 57 | 0.020 |
Why?
| | Luciferases | 1 | 2006 | 142 | 0.020 |
Why?
| | Risk Assessment | 1 | 2015 | 2968 | 0.020 |
Why?
| | Mutation | 1 | 1996 | 3345 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2007 | 620 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2006 | 129 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2006 | 257 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2006 | 166 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 811 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2012 | 2186 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2010 | 1076 | 0.010 |
Why?
| | Hypoxia | 1 | 2010 | 957 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2007 | 1430 | 0.010 |
Why?
| | Prospective Studies | 1 | 2014 | 6219 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 1796 | 0.010 |
Why?
| | Androgens | 1 | 2003 | 167 | 0.010 |
Why?
| | RNA, Neoplasm | 2 | 1992 | 80 | 0.010 |
Why?
| | Gene Library | 2 | 1992 | 114 | 0.010 |
Why?
| | DNA Footprinting | 1 | 2000 | 28 | 0.010 |
Why?
| | Plasmids | 2 | 1992 | 343 | 0.010 |
Why?
| | Aging | 1 | 2010 | 1618 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 736 | 0.010 |
Why?
| | Lentivirus | 1 | 2000 | 44 | 0.010 |
Why?
| | Fibroblast Growth Factor 8 | 1 | 2000 | 27 | 0.010 |
Why?
| | Scintillation Counting | 1 | 2000 | 3 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 2000 | 25 | 0.010 |
Why?
| | 3T3 Cells | 1 | 2000 | 140 | 0.010 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2000 | 49 | 0.010 |
Why?
| | Stromal Cells | 1 | 2000 | 96 | 0.010 |
Why?
| | Transduction, Genetic | 1 | 2000 | 113 | 0.010 |
Why?
| | Carbonic Anhydrase IX | 1 | 2000 | 3 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2000 | 68 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2000 | 201 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 2 | 1992 | 187 | 0.010 |
Why?
| | Desmoplakins | 1 | 2000 | 19 | 0.010 |
Why?
| | Rats | 3 | 1993 | 4958 | 0.010 |
Why?
| | Prostatic Intraepithelial Neoplasia | 1 | 1999 | 12 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2000 | 195 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2000 | 289 | 0.010 |
Why?
| | Isoenzymes | 1 | 2000 | 283 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2000 | 338 | 0.010 |
Why?
| | Neuroendocrine Secretory Protein 7B2 | 2 | 1989 | 2 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2000 | 154 | 0.010 |
Why?
| | Loss of Heterozygosity | 1 | 1999 | 40 | 0.010 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2000 | 111 | 0.010 |
Why?
| | Organ Specificity | 1 | 2000 | 268 | 0.010 |
Why?
| | Diet | 1 | 2006 | 1080 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2000 | 470 | 0.010 |
Why?
| | United States | 1 | 2014 | 12181 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 743 | 0.010 |
Why?
| | Helix-Loop-Helix Motifs | 1 | 1997 | 11 | 0.010 |
Why?
| | beta Catenin | 1 | 2000 | 219 | 0.010 |
Why?
| | Sp1 Transcription Factor | 1 | 1997 | 23 | 0.010 |
Why?
| | Base Composition | 1 | 1997 | 75 | 0.010 |
Why?
| | Dinucleoside Phosphates | 1 | 1997 | 24 | 0.010 |
Why?
| | Cell Survival | 1 | 2000 | 1021 | 0.010 |
Why?
| | Sequence Deletion | 1 | 1997 | 167 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 286 | 0.010 |
Why?
| | Egypt | 1 | 1996 | 10 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1989 | 2177 | 0.010 |
Why?
| | Netherlands | 1 | 1996 | 64 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2000 | 1230 | 0.010 |
Why?
| | Single-Strand Specific DNA and RNA Endonucleases | 1 | 1994 | 10 | 0.010 |
Why?
| | Sequence Homology | 1 | 1994 | 39 | 0.010 |
Why?
| | TATA Box | 1 | 1994 | 22 | 0.010 |
Why?
| | DNA Probes | 1 | 1994 | 59 | 0.010 |
Why?
| | Chickens | 1 | 1994 | 177 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 1995 | 151 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1994 | 294 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1995 | 442 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2000 | 1314 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1993 | 152 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1993 | 187 | 0.010 |
Why?
| | Kidney | 1 | 1998 | 1188 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 385 | 0.010 |
Why?
| | Epitopes | 1 | 1993 | 435 | 0.010 |
Why?
| | Biological Evolution | 1 | 1994 | 416 | 0.010 |
Why?
| | Transcription Factors | 1 | 1997 | 1528 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1989 | 158 | 0.000 |
Why?
| | Asialoglycoprotein Receptor | 1 | 1988 | 4 | 0.000 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1988 | 211 | 0.000 |
Why?
| | Protein Conformation | 1 | 1988 | 805 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1988 | 506 | 0.000 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1989 | 961 | 0.000 |
Why?
| | Adolescent | 1 | 1998 | 17841 | 0.000 |
Why?
|
|
Van Bokhoven's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|